Biology Reference
In-Depth Information
Schmiechen R, Schneider HH,Wachtel H (1990) Close correlation between behavioural response and
binding in vivo for inhibitors of rolipram-sensitive phosphodiesterase. Psychopharmacology
102:17-20
Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the
antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115
Schroeder Wv (1887) Ueber die Wirkung des Coffeins als Diuretikum. Arch Exp Path Pharmacol
22:39-61
Schudt C, Winder S, Eltze M, Kilian U, Beume R (1991a) Zardaverine: a cyclic AMP specific PDE
III/IV inhibitor. Agents Actions (Suppl) 34:379-402
Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V (1991b) Influence of selective
phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca
i
.
Naunyn-Schmiedeberg's Arch Pharmacol 344:682-690
Schudt C, Winder S, Mueller B, Ukena D (1991c) Zardaverine as a selective inhibitor of
phosphodiesterase isozymes. Biochem Pharmacol 42:153-161
Schudt C, Tenor H, Wendel A, Eltze M, Magnussen H, Rabe KF (1993) Influence of the PDEIII/IV
inhibitor B9004-070 on contraction and PDE activities in airway and vascular smooth muscle.
Am Rev Respir Dis 147:A183
Semmler J, Wachtel H, Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram
suppresses tumor necrosis factor-
a
production by human mononuclear cells. Int J Immuno-
pharmac 15:409-413
Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM, Giembycz MA
(1998) Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in
human peripheral blood T-lymphocytes by 8-bromo-cAMP and G
s
-coupled receptor agonists.
J Biol Chem 273:20575-20588
Simet SM, Sisson JH, Pavlik JA, Devasure JM, Boyer C, Liu X, Kawasaki S, Sharp JG, Rennard
SI, Wyatt TA (2009) Long-term cigarette smoke exposure in a mouse model of ciliated
epithelial cell function. Am J Respir Cell Mol Biol 43(6):635-640
Souness JE (1996) Characterization of different states of PDE4 by rolipram and RP 73401. In:
Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic, London
Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman N, Karlsson J-A
(1996) Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF generation from
human monocytes by interacting with a “low affinity” phosphodiesterase 4 conformer. Br J
Pharmacol 118:649-658
Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodies-
terase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a
“low-affinity” phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750
Stawiski MA, Rusin LJ, Burns TL, Weinstein GD, Voorhees JJ (1979) Ro 20-1724: an agent that
significantly improves psoriatric lesions in double-blind clinical trials. J Invest dermatol 73:261-263
Takeyama K, Jung B, Shim JJ, Burgel PR, Dao-Pick T, Ueki IF, Protin U, Kroschel P,
Nadel JA (2001) Activation of epidermal growth factor receptors is responsible for mucin
synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 280:L165-72
Tenor H, Schudt C (1996) Analysis of PDE isoenzyme profiles in cells and tissues by
pharmacological methods. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors.
Academic, London
Tenor H, Hatzelmann A, Wendel A, Schudt C (1995a) Identification of phosphodiesterase IV
activity and its cyclic adenosine monophosphate-dependent up-regulation in a human
keratinocyte cell line (HACAT). J Invest Dermatol 105:70-74
Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanovic R, Church MK, Shute JK
(1995b) Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T
lymphocytes. Clin Exp Allergy 25:616-624
Tenor H, Hatzelmann A, Kupferschmidt R, Staniciu L, Djukanovic R, Schudt C, Wendel A,
Church MK, Shute JK (1995c) Cyclic nucleotide phosphodiestererase isoenzyme activities in
human alveolar macrophages. Clin Exp Allergy 25:625-6333
